Search
Grifols SA
GRFSAdd to Watchlist
7.870USD
-0.330-4.02%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.03BMarket Cap
10.14P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Grifols SA is 7.00, ranking 112 out of 155 in the Pharmaceuticals industry. The average price target is 12.20, with a high of 12.20 and a low of 12.20.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
11.730
Target Price
+43.93%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Grifols SA
GRFS
8
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Grifols SA's expected revenue for the next quarter?
Grifols SA's expected revenue is 2.26B.
What is Grifols SA's price target?
Analysts forecast that Grifols SA's price target is USD 12.20, with the highest forecast at USD 12.20 and the lowest forecast at USD 12.20.
How have Grifols SAGRFS's recent earnings per share performed?
The market expectation was USD 0.20, while Grifols SAGRFS's earnings per share (EPS) for the previous quarter was USD 0.17. EPS for the next quarter is expected at USD 0.28.
What is the analyst rating for Grifols SA?
Based on the ratings of Grifols SA's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.